BRAF L505H

CI-VAR-00002354Explore in graph →NP_004324.2:p.Leu505HisNM_004333.4:c.1514T>ACIViC 658

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
BRAF L505H	Vemurafenib	Predictive	B	Supports Resistance	3	accepted	EID1669 In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutatio… (full text at CIViC) PMID 25515853 · Hoogstraat et al., 2015 · Open in CIViC	civic
BRAF L505H	Vemurafenib	Predictive	D	Supports Resistance	4	accepted	EID1668 Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L… (full text at CIViC) PMID 24112705 · Wagenaar et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.